- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04883749
Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL (CLL-Frail)
March 22, 2024 updated by: German CLL Study Group
CLL-Frail - A Prospective, Multicenter Phase II Trial of Acalabrutinib in Very Old (≥80y) or Frail CLL-Patients
The aim of this trial is to show the efficacy, safety and feasibility of acalabrutinib in a cohort of CLL-patients ≥80 years or with a FRAIL scale score >2 (5-item questionnaire to be filled out by the patient)
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
53
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Barbara Eichhorst, Prof.
- Phone Number: +49 221 478 88220
- Email: barbara.eichhorst@uk-koeln.de
Study Contact Backup
- Name: Florian Simon, Dr.
- Phone Number: +49 221 478 88220
- Email: florian.simon@uk-koeln.de
Study Locations
-
-
-
Innsbruck, Austria, 6020
- Medizinische Universitat Innsbruck
-
Wien, Austria, 1140
- Hanusch Krankenhaus
-
-
-
-
-
Berlin, Germany, 10707
- Onkologische Schwerpunktpraxis Kurfürstendamm
-
Deggendorf, Germany, 94469
- Donau-Isar-Klinikum Deggendorf Hämatologie/Onkologie
-
Erlangen, Germany, 91052
- Oncoresearch Institut für klinische Studien GbR
-
Essen, Germany, 45147
- Universitaetsklinikum Essen
-
Goslar, Germany, 38642
- Onkologische Kooperation Harz
-
Hamburg, Germany, 22081
- OncoResearch Lerchenfeld
-
Hannover, Germany, 30171
- MediProjekt GBR
-
Kiel, Germany, 24105
- Universitaetsklinikum Schleswig-Holstein Campus Kiel
-
Koblenz, Germany, 56068
- Praxis fuer Haematologie und Onkologie
-
Köln, Germany, 50937
- Universitätsklinik Köln
-
Landshut, Germany, 84036
- H.O.T Praxis Landshut
-
Lübeck, Germany, 23562
- Lübecker Onkologische Schwerpunktpraxis
-
Magdeburg, Germany, 39104
- Gemeinschaftspraxis Haematologie und Onkologie
-
Muenster, Germany, 48153
- Gemeinschaftspraxis für Hämatologie und Onkologie
-
Paderborn, Germany, 33098
- Brüderkrankenhaus St. Josef Paderborn
-
Ravensburg, Germany, 88212
- Gemeinschaftspraxis für Hämatologie und Onkologie
-
Ulm, Germany, 89081
- Universitaetsklinikum Ulm
-
Würzburg, Germany, 97080
- Hämatologisch Onkologische Schwerpunktpraxis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥80 years AND/OR considered too frail for intensive/standard treatment defined by a frailty score of >2 on the FRAIL scale via the patient´s assessment.
- Have documented CLL requiring treatment according to iwCLL 2018 criteria
- Ability and willingness to provide written informed consent and to adhere to the study visit schedule and other protocol requirements
- Glomerular Filtration Rate (GFR) >30ml/min directly measured with 24hr urine collection, calculated according to the modified formula of Cockcroft and Gault (for men: GFR ≈ ((140 - age) x bodyweight)/ (72 x creatinine), for women x 0, 85) or an equally accurate method (Please note: Patients currently on hemodialysis are excluded from participating in the trial)
- Adequate liver function as indicated by a total bilirubin ≤ 3 x, Aspartate-Aminotransferase/Alanin-Aminotransferase (AST/ ALT) ≤ 3 x the institutional Upper Limit of Normal (ULN) value, unless directly attributable to the patient's CLL or to Gilbert's Syndrome
Adequate marrow function independent of growth factor or transfusion support as follows, unless cytopenia is due to marrow involvement of CLL:
- Absolute neutrophil count ≥ 1.0 × 10^9/L
- Platelet counts ≥ 30 × 10^9/L; in cases of thrombocytopenia clearly due to marrow involvement of CLL (per the discretion of the investigator); platelet count should be ≥ 10 × 10^9/L if there is bone marrow involvement
- Total haemoglobin ≥ 9 g/dL (without transfusion support, unless anaemia is due to marrow involvement of CLL)
- Negative serological testing for hepatitis B (HBsAg negative and anti-HBc negative; patients positive for anti-HBc may be included if PCR for HBV DNA is negative and HBV-DNA Polymerase Chain Reaction (PCR) is performed every month until 12 months after last month of treatment), negative testing for hepatitis C RNA within 6 weeks prior to registration
- Life expectancy ≥ 3 months
- Maximum of 1 previous treatment for CLL
In case of a recent previous treatment, patients must have recovered from acute toxicities and treatment regimen must be stopped within the following time periods before start of the study treatment in the CLL-Frail trial:
- chemotherapy ≥ 28 days
- antibody treatment ≥ 14 days
- kinase inhibitors (see also exclusion criterion 6), BCL2-antagonists or immunomodulatory agents ≥ 3 days
- corticosteroids may be applied until the start of the study therapy, these have to be reduced to an equivalent of ≤ 20 mg prednisolone per day during treatment
- Signed informed consent and, in the investigator's judgment, able to comply with the study protocol
Exclusion Criteria:
- >1 prior CLL-specific therapy (except corticosteroid treatment administered due to necessary immediate intervention; within the last 14 days before start of study treatment, only dose equivalents up to 20 mg prednisolone are permitted)
- Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) e.g. Richter's transformation or prolymphocytic leukaemia
- Patients with a history of confirmed progressive multifocal leukoencephalopathy (PML)
- Patients with uncontrolled autoimmune haemolytic anaemia or immune thrombocytopenia
- Prior exposure to acalabrutinib
- Progression during previous treatment with another BTK inhibitor, and/or presence of known mutations associated with resistance to therapy, e.g. Bruton´s Tyrosine Kinase (BTK) and Phospholipase C Gamma 2 (PLCg2)
- Uncontrolled concomitant malignancy, i.e. any concomitant malignancy that may compromise the assessment of CLL stage and the response assessment of the study treatment
- Eastern Cooperative Oncology Group Performance Status (ECOG) performance status >3
- Uncontrolled or active infection (including positive SARS-Cov-2 PCR result)
- Patients with known infection with human immunodeficiency virus (HIV)
- Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 3 months of screening, or any class 4 cardiac disease as defined by the New York Heart Association Functional Classification at Screening (Please note: Subjects with controlled, asymptomatic atrial fibrillation are allowed to enroll on study)
- Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening
- Significantly increased risk of bleeding according to the investigator´s evaluation, e.g. due known bleeding diathesis (e.g. von-Willebrandt´s disease or hemophilia), major surgical procedure ≤ 4 weeks or stroke/intracranial hemorrhage ≤ 6 months
- Use of investigational agents which might interfere with the study drug within 28 days prior to registration for study screening
- Requirement of therapy with strong CYP3A4 inhibitors/inducers or anticoagulant with phenprocoumon (marcumar) or other vitamin K-antagonists (Please note: Switch to alternative anticoagulants for vitamin K antagonists is permitted)
- Inability to swallow tablets
- Legal incapacity
- Prisoners or subjects who are institutionalized by regulatory or court order
- Persons who are in dependence to the sponsor or an investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Acalabrutinib
Acalabrutinib will be administered up to 24 cycles (= approx.
24 months total) until progression of disease (PD) or intolerable toxicity
|
Cycle (q28d): Acalabrutinib p.o.100 mg twice daily (BID)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR) at initial response assessment
Time Frame: At initial response assessment (approx. 6 months after initiation of therapy)
|
Proportion of patients having achieved complete response (CR), complete response with incomplete bone marrow recovery (CRi) or partial response (PR) as response (according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 guidelines)
|
At initial response assessment (approx. 6 months after initiation of therapy)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR at final restaging
Time Frame: At final restaging (approx. 24 months after initiation of therapy)
|
Proportion of patients having achieved complete response (CR), complete response with incomplete bone marrow recovery (CRi) or partial response (PR) as response (according to the iwCLL 2018 guidelines)
|
At final restaging (approx. 24 months after initiation of therapy)
|
Overall survival (OS)
Time Frame: Up to 24 month
|
Time from the date of registration to the date of death due to any cause
|
Up to 24 month
|
Progression-free survival (PFS)
Time Frame: Up to 24 month
|
Time from the date of registration to the date of first occurrence of disease progression or relapse (according to iwCLL 2018 criteria) or death from any cause, whichever occurs first
|
Up to 24 month
|
Event-free survival (EFS)
Time Frame: Up to 24 month
|
Time from the date of registration to the first occurrence of progression or relapse (according to iwCLL 2018 criteria), death from any cause or initiation of a subsequent anti-leukemic treatment, whichever occurs first
|
Up to 24 month
|
Time to next CLL treatment (TTNT).
Time Frame: Up to 24 month
|
Time from date of registration to the date of initiation of subsequent anti-leukemic treatment
|
Up to 24 month
|
Safety parameters: Adverse events (AE) and adverse events of special interest (AESI)
Time Frame: Up to 24 month
|
Type, frequency, and severity of AEs and AESIs
|
Up to 24 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Barbara Eichhorst, Prof., Department I of Internal Medicine, University Hospital Cologne
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2021
Primary Completion (Actual)
July 31, 2023
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
May 7, 2021
First Submitted That Met QC Criteria
May 7, 2021
First Posted (Actual)
May 12, 2021
Study Record Updates
Last Update Posted (Actual)
March 25, 2024
Last Update Submitted That Met QC Criteria
March 22, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Hematologic Diseases
- Leukemia
- Leukemia, B-Cell
- Chronic Disease
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Acalabrutinib
Other Study ID Numbers
- CLL-Frail
- 2020-002142-17 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphoid Leukemia
-
University Hospital TuebingenGlaxoSmithKlineRecruitingChronic Lymphoid Leukemia in RelapseGermany
-
University Hospital, BrestRecruitingChronic Lymphoid LeukaemiaFrance
-
Dana-Farber Cancer InstituteAcetylon Pharmaceuticals IncorporatedActive, not recruitingRecurrent Chronic Lymphoid LeukemiaUnited States
-
University Hospital, ToulouseRecruitingChronic Lymphoid LeukemiaFrance
-
French Innovative Leukemia OrganisationRecruiting
-
German CLL Study GroupCancer Trials Ireland; Stichting Hemato-Oncologie voor Volwassenen Nederland... and other collaboratorsActive, not recruitingChronic Lymphoid LeukemiaSpain, Ireland, Austria, Denmark, Israel, Norway, Germany, Switzerland, Italy, Belgium, Finland, Sweden, Netherlands
-
Semmelweis UniversityTerminatedChronic Lymphoid LeukemiaHungary
-
Memorial Sloan Kettering Cancer CenterTerminatedHodgkin Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML) | Acute Lymphoid Leukemia (ALL)United States
-
German CLL Study GroupCompleted
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedB-cell Lymphoid Leukemia | Young PatientsItaly
Clinical Trials on Acalabrutinib
-
AstraZenecaAcerta Pharma, LLCCompletedPharmacokinetics | BioavailabilityUnited States
-
AstraZenecaParexelCompletedCOVID-19 | Mantle Cell LymphomaGermany
-
Acerta Pharma BVAstraZenecaActive, not recruitingMantle Cell Lymphoma (MCL)United States, Poland, Italy
-
Acerta Pharma BVNational Institutes of Health (NIH)Active, not recruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Acerta Pharma BVAstraZenecaCompletedHepatic Insufficiency | Healthy Subjects | Hepatic ImpairmentUnited States
-
Acerta Pharma BVActive, not recruitingChronic Lymphocytic LeukemiaUnited States, United Kingdom, Belgium, Spain, Israel, France
-
AstraZenecaCompletedBioequivalenceUnited States
-
AstraZenecaCompletedChronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell LymphomaIndia
-
Acerta Pharma BVActive, not recruitingGlioblastoma MultiformeUnited States
-
Acerta Pharma BVActive, not recruitingMantle Cell Lymphoma (MCL)Belgium, France, United Kingdom, United States, Italy, Poland, Netherlands, Australia, Czechia, Spain